Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Bullboard Posts
Post by Realityck1on Feb 17, 2020 10:08am
173 Views
Post# 30698966

US Market hates the optics; shareholders suffer

US Market hates the optics; shareholders sufferIf you have something to bury you release it on a friday, better yet a friday of a long weekend. Why did they need to hold this call midday on the friday of a long weekend? Do they have no business sense at all? These optics just add to the pathetic story.
Pierre was a disaster - rambled, said too much, while saying nothing helpful  - he should have had prepared answers; they should have anticipated what questions they would get. IMO it was a great question by the one analyst - about what were the results of the other 49 sites. Why Jan chose to dodge that answer is disappointing and frustrating (the stock answer of we are not releasing anymore info at this time). Do they realize there are shareholders who have been with them 10++yrs who are going down with the ship? Do they even care - obviously not. They might if a class action emerges in the future.
We deserved better answers and fuller answers. We're now looking at another 7 to 8 months before we have any more answers - yet is management withholding their own salary - nope. Just us - we, the shareholders are bearing this suffering. And to me the reason seems pretty clear - some incompetence person or persons did not enforce (or construct) the study protocol properly; either that or the makers of cornstarch just changed their composition to successfully combat high cholesterol.
I wish someone would have asked why George Heywood all of a sudden reduced his significant holdings in Acasti - timing seems interesting - if the reports are correct then he seems to have substantially reduced his holdings during the delay over the Christmas period - you know the time when the stock price was still decent. And who again orchestrated that delay... hmmm
Wish we small guys would have known certain info too..... instead all our money remains dead and dying for the next 8 months. Thanks Pierre and Jan. Hope you two are enjoying your regular paychecks.
Bullboard Posts